Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

ABSTRACT: A prospective, multicentre, open-label, randomized, phase 2-3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer

DISEASE(S): Metastatic Colorectal Cancer,Cáncer Colorrectal Metastásico Después De 2 O 3 Líneas De Tratamiento,Colorectal Neoplasms,Colorectal Cancer Metastatic,Metastatic Colorectal Cancer After 2 Or 3 Previous Lines Of Treatment

PROVIDER: 2275369 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR